Corcept Therapeutics reported $1.03B in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Alaunos Therapeutics USD 1.52M 367K Jun/2026
ANI Pharmaceuticals USD 1.57B 73.55M Sep/2026
Ardelyx USD 587.52M 11.63M Sep/2026
Aurora Cannabis CAD 620.88M 19.79M Jun/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Canopy Growth CAD 1.1B 14.81M Jun/2026
Corcept Therapeutics USD 1.03B 145.32M Sep/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Knight Therapeutics CAD 1.05B 2.28M Dec/2025
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
Merck USD 132.77B 2.97B Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novartis USD 117.15B 4.88B Sep/2026
Novartis USD 117.15B 1.38B Sep/2026
Omeros USD 200.57M 34.59M Jun/2025
Pfizer USD 204.54B 3.41B Sep/2026
Supernus Pharmaceuticals USD 1.4B 30.42M Sep/2026
TG Therapeutics USD 1.59B 47.38M Sep/2026